2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD

Description

Evaluate and study the immunologic changes to the ocular surface in cancer patients.

Conditions

Dry Eye Disease, oGVHD

Talk to us

Study Overview

On this page

Study Details

Study overview

Evaluate and study the immunologic changes to the ocular surface in cancer patients.

2177GCCC: Identifying Novel Treatment Targets and Biomarkers for Ocular Surface Disease in Patients With Ocular Graft vs Host Disease (oGVHD) a Biobank Study

2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD

Condition
Dry Eye Disease
Intervention / Treatment

-

Contacts and Locations

Baltimore

Geenebaum Cancer Center, University of Maryland Medical Center, Baltimore, Maryland, United States, 21201

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult patients (≥ 18 years of age) who visit the Eye clinic either in the UMGCCC within the UMD Hospital or the UMD Faculty Physicians Ophthalmology Practice at the UMD Professional Building or satellite locations for initial visits or established visits.
  • * The patient must be able to understand and sign and date the informed consent form approved by the IRB.
  • * Vulnerable populations: neonates, children, prisoners, institutionalized individuals.
  • * Inability or refusal to provide informed consent.
  • * History of ocular surgery (except refractive surgery or cataract surgery)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Maryland, Baltimore,

Sarah Sunshine, MD, PRINCIPAL_INVESTIGATOR, University of Maryland, Baltimore

Study Record Dates

2025-12-31